Suppression of inflammation in ulcerative colitis by interferon-β-1a is accompanied by inhibition of IL-13 production
Open accessThe DOI matches its Crossref record.
Abstract
Objective: Ulcerative colitis is associated with increased interleukin 13 (IL-13) production by natural killer T cells. Taking advantage of the inhibitory actions of interferon β on IL-13 expression, this proof-of-concept study aimed to show that decreasing IL-13 production is associated with clinical improvement of ulcerative colitis symptoms. Design: Open-label interventional drug trial. Setting: Outpatient clinical research hospital. Patients: Adult patients with active ulcerative colitis (Short Clinical Colitis Activity Index (SCCAI)≥5). Interventions: Treatment with 30 μg IM interferon-β-1a (Avonex) weekly for 12 weeks with 6 month follow-up. Main outcome measures: Clinical response was defined as ≥3 point drop in the SCCAI for at least two consecutive monitoring visits, and cytokine production was measured in cultured peripheral blood and lamina propria mononuclear cells (LPMC) before and after treatment. Results: 11 of 16 patients were clinical responders, and 4 were in remission (SCCAI ≤ 2) at the end of treatment. Rectal bleeding subscores improved dramatically by week 4 (38% with frank bleeding vs 87% pretreatment). Increased IL-13 production by LPMC T cells fell significantly in clinical responders (690±99 vs 297±58 pg/ml p=0.015) but was unchanged in non-responders (542±83 vs 510±39 pg/ml). In addition, non-responders had significantly higher production of IL-17 and IL-6 pre-treatment compared to responders. Conclusions: Interferon-β-1a induces clinical response and remission in a large subset of patients with ulcerative colitis that is associated with significant inhibition of IL-13 production. In addition, increased IL-17 and IL-6 production is associated with no response to interferon-β. These data provide a proof-of-concept that IL-13 is an effector cytokine in ulcerative colitis and should be a target for novel therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cytokines in inflammatory bowel disease
Neurath, M. F. (2014) · Nature Reviews Immunology · doi:10.1038/nri3661 · Cited by 2,706
Proinflammatory Cytokines in the Pathogenesis of Inflammatory Bowel Diseases
Strober, W., & Fuss, I. J. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.016 · Cited by 1,102
Self-citationDanese, S., & Fiocchi, C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1102942 · Cited by 1,102
Johansson, M. E. V., Gustafsson, J. K., Holmén-Larsson, J., Jabbar, K. S., Xia, L., Xu, H., Ghishan, F. K., Carvalho, F. A., Gewirtz, A. T., Sjövall, H., et al. (2014) · Gut · doi:10.1136/gutjnl-2012-303207 · Cited by 1,004
Toll-like Receptors and Inflammatory Bowel Disease
Lu, Y., Li, X., Liu, S., Zhang, Y., & Zhang, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00072 · Cited by 341
New therapies for inflammatory bowel disease: from the bench to the bedside
Danese, S. (2012) · Gut · doi:10.1136/gutjnl-2011-300904 · Cited by 308
Changes of the cytokine profile in inflammatory bowel diseases
Műzes, G. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i41.5848 · Cited by 250
Yu, L., Yan, J., & Sun, Z. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6241 · Cited by 189
Janus‐like effects of type I interferon in autoimmune diseases
Axtell, R. C., & Raman, C. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01131.x · Cited by 47
Metadata
- Authors
- Mannon, P. J., Hornung, R. L., Yang, Z., Yi, C., Groden, C., Friend, J., Yao, M., Strober, W., & Fuss, I. J.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2010-10-22
- Volume
- 60
- Issue
- 4
- Pages
- 449-455
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2155488733
- Cited by
- 92
- References
- 0
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.